Powered by the Evidence-based Practice Centers
SHARE:
FacebookTwitterFacebookPrintShare

Gene Expression Profiling for Predicting Outcomes in Stage II Colon Cancer

Technical Brief ARCHIVED Dec 14, 2012

Documents

People using assistive technology may not be able to fully access information in these files. For additional assistance, please contact us.

Archived: This report is greater than 3 years old. Findings may be used for research purposes, but should not be considered current.

Structured Abstract

Background

While adjuvant chemotherapy is recommended in patients with stage III colon cancer, its role in stage II disease is unclear. In treating 100 stage II patients with adjuvant chemotherapy, three or four will benefit, while others will suffer significant adverse effects. Research is underway to improve this decisionmaking. Gene expression profiling (GEP) is one of the techniques being studied.

Purpose

The objective of this Technical Brief is to provide a summary of the state of the science on use of GEP in predicting outcomes, including benefit from adjuvant chemotherapy, in patients with stage II colon cancer. This Brief also summarizes key uncertainties.

Methods

The objective of this Technical Brief is to provide a summary of the state of the science on use of GEP in predicting outcomes, including benefit from adjuvant chemotherapy, in patients with stage II colon cancer. This Brief also summarizes key uncertainties.

Findings

The objective of this Technical Brief is to provide a summary of the state of the science on use of GEP in predicting outcomes, including benefit from adjuvant chemotherapy, in patients with stage II colon cancer. This Brief also summarizes key uncertainties.

Conclusion

Although information is emerging about use of GEP assays to inform the decision about use of adjuvant chemotherapy in patients with stage II colon cancer, studies to date have not provided the type of information needed to address major uncertainties.

Project Timeline

Gene Expression Profiling for Predicting Outcomes in Stage II Colon Cancer

Mar 13, 2012
Topic Initiated
Mar 13, 2012
Dec 14, 2012
Technical Brief Archived
Page last reviewed December 2019
Page originally created November 2017

Internet Citation: Technical Brief: Gene Expression Profiling for Predicting Outcomes in Stage II Colon Cancer. Content last reviewed December 2019. Effective Health Care Program, Agency for Healthcare Research and Quality, Rockville, MD.
https://effectivehealthcare.ahrq.gov/products/colon-cancer-gene-profiling/technical-brief

Select to copy citation